Day 4 Program

Poster Spotlight 14: Late Breaking Abstracts 

Day 4: December 11, 2026

7:00 AM–8:30 AM CST

Hemisfair 1-2

Session Details

Moderator

Frederick M. Howard, University of Chicago

PS14-1

Prospective-retrospective HeCOG phase III trial validation study of a multimodal AI model for 5-year and 10-year distant metastasis risk assessment in early HR+/HER2- breast cancer

Marta Ligero, StratifAI GmbH, Berlin, Germany

PS14-2

Multi-institutional validation of a computational pathology model for late recurrence risk stratification in hormone receptor-positive breast cancer

Satvika Bharadwaj, Georgia Institute of Technology and Emory University, Atlanta, GA

PS14-4

Performance of the Sensitivity to Endocrine Therapy (SET<sub>ER/PR</sub>) assay in the ECOG-ACRIN TAILORx trial

Joseph Sparano, Icahn School of Medicine at Mount Sinai, New York, NY

PS14-5

Integration of molecular and pathologic response to neoadjuvant therapy (NAT) could inform risk stratification across response-predictive subtypes in high-risk early-stage breast cancer: Results from >1,200 patients in the I-SPY2 trial

Mark Jesus Magbanua, University of California San Francisco, San Francisco, CA

PS14-6

Ultrasensitive whole genome sequencing tumor informed ctDNA monitoring is highly prognostic and detects molecular recurrence years before clinical relapse in early HR+/HER2- breast cancer

Felicity C Martin, Department of Oncology, University of Cambridge; Precision Breast Cancer Institute, Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom

PS14-7

Spatial Arrangement of AI-Predicted HER2 Expression from Hematoxylin and Eosin Improves Prediction of Pathologic Complete Response Beyond PAM50 in the NSABP B-41 Trial

Sahar Almahfouz Nasser, Emory University, Atlanta, GA

PS14-8

Blinded external validation of an H&E image-based early distant recurrence (EDR) model for 5-year distant recurrence-free survival in SWOG S1007 (RxPONDER)

Funda Meric-Bernstam, UT MD Anderson Cancer Center, Houston, TX

PS14-9

Independent Validation of the HER2DX CNS Progression Score in the Pertuzumab Arm of the Phase III CLEOPATRA Trial

Rodrigo Sanchez-Bayona, Hospital Universitario 12 de Octubre. Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain